[{"id":"64497f54-38a5-401a-93f0-04cf9d26aa99","acronym":"ACCELERATE","url":"https://clinicaltrials.gov/study/NCT07013565","created_at":"2025-06-14T14:00:13.949Z","updated_at":"2025-06-14T14:00:13.949Z","phase":"Phase 2","brief_title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","source_id_and_acronym":"NCT07013565 - ACCELERATE","lead_sponsor":"New York Medical College","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • vinblastine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-06-10"},{"id":"1a7e9bb9-7b86-4b0f-bf52-ec51de4a9d98","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03113500","created_at":"2021-01-18T15:20:28.612Z","updated_at":"2025-02-25T14:01:16.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03113500 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/25/2017","start_date":" 05/25/2017","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2025-02-19"},{"id":"574c26d5-ccf2-4a95-b75d-6e8c523c2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588651","created_at":"2021-01-18T12:33:39.552Z","updated_at":"2025-02-25T14:49:58.459Z","phase":"Phase 2","brief_title":"A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (\u003c10%) Mature T Cell Lymphoma (TCL)","source_id_and_acronym":"NCT02588651","lead_sponsor":"Deepa Jagadeesh","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/17/2016","start_date":" 06/17/2016","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 10/14/2024","study_completion_date":" 10/14/2024","last_update_posted":"2025-02-13"},{"id":"14db2cea-3400-48ac-8ad3-0b56fccbb5a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03007030","created_at":"2021-01-18T14:47:28.350Z","updated_at":"2025-02-25T15:42:55.122Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03007030","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-10"},{"id":"a5ee75a6-412a-4439-adb0-ad0586456a5d","acronym":"LCCC1637","url":"https://clinicaltrials.gov/study/NCT03264131","created_at":"2021-01-18T16:07:30.882Z","updated_at":"2025-02-25T15:42:58.677Z","phase":"Phase 2","brief_title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","source_id_and_acronym":"NCT03264131 - LCCC1637","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2028","study_completion_date":" 12/15/2028","last_update_posted":"2025-02-10"},{"id":"fdf5903a-380e-4274-bdb7-c41fd2578d9b","acronym":"NCI-2022-03831","url":"https://clinicaltrials.gov/study/NCT05357794","created_at":"2022-05-03T15:54:14.202Z","updated_at":"2025-02-25T15:35:38.204Z","phase":"Phase 2","brief_title":"Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides","source_id_and_acronym":"NCT05357794 - NCI-2022-03831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-10"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"6eaf7ebc-3a8d-431d-b6e5-611012b34a31","acronym":"KEYNOTE B81","url":"https://clinicaltrials.gov/study/NCT04609566","created_at":"2021-01-19T20:32:09.814Z","updated_at":"2025-02-25T16:10:46.045Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors","source_id_and_acronym":"NCT04609566 - KEYNOTE B81","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-07"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"b0562de4-83b5-474a-a0ea-2bf447d40f13","acronym":"SGN35-032","url":"https://clinicaltrials.gov/study/NCT04569032","created_at":"2021-01-18T21:49:19.024Z","updated_at":"2025-02-25T16:38:04.380Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression","source_id_and_acronym":"NCT04569032 - SGN35-032","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 05/09/2024","primary_completion_date":" 05/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e4ee9c8a-52e5-4407-8d69-cf484bfda0df","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352520","created_at":"2021-01-18T05:31:44.732Z","updated_at":"2025-02-25T16:43:37.647Z","phase":"Phase 2","brief_title":"SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)","source_id_and_acronym":"NCT01352520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-05"},{"id":"c3e37946-e4b9-4544-a60c-995c415bbbe7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06563778","created_at":"2025-02-26T10:28:05.577Z","updated_at":"2025-02-26T10:28:05.577Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","source_id_and_acronym":"NCT06563778","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-08-21"},{"id":"0e15a431-fa68-4600-8321-5e50101e95ba","acronym":"EATL-001","url":"https://clinicaltrials.gov/study/NCT03217643","created_at":"2021-01-18T15:52:35.192Z","updated_at":"2025-02-25T14:50:36.812Z","phase":"Phase 2","brief_title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","source_id_and_acronym":"NCT03217643 - EATL-001","lead_sponsor":"Imagine Institute","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • carmustine"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2024-06-19"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"5dee7c2d-c458-4efc-8ddb-50ee403de9bf","acronym":"SGN35-015","url":"https://clinicaltrials.gov/study/NCT01716806","created_at":"2021-01-18T07:28:55.529Z","updated_at":"2024-07-02T16:34:27.249Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01716806 - SGN35-015","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 10/31/2012","start_date":" 10/31/2012","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2024-06-11"},{"id":"144749df-0a66-4aa2-9a78-56b647da62a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05313243","created_at":"2022-04-06T14:52:59.872Z","updated_at":"2025-02-25T16:17:33.219Z","phase":"Phase 2","brief_title":"Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma","source_id_and_acronym":"NCT05313243","lead_sponsor":"Yale University","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-06-05"},{"id":"9305d049-0937-4efb-b533-d227aca1a1be","acronym":"","url":"https://clinicaltrials.gov/study/NCT01492088","created_at":"2021-01-18T06:14:41.157Z","updated_at":"2024-07-02T16:35:00.094Z","phase":"Phase 1/2","brief_title":"Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma","source_id_and_acronym":"NCT01492088","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" ALK • TNFRSF8","pipe":"","alterations":" ","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/16/2012","start_date":" 04/16/2012","primary_txt":" Primary completion: 10/12/2016","primary_completion_date":" 10/12/2016","study_txt":" Completion: 04/12/2018","study_completion_date":" 04/12/2018","last_update_posted":"2024-05-30"},{"id":"84dc5381-b2bd-414d-95d6-7e4b13384698","acronym":"","url":"https://clinicaltrials.gov/study/NCT01771107","created_at":"2021-01-18T07:48:13.309Z","updated_at":"2024-07-02T16:35:02.686Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma","source_id_and_acronym":"NCT01771107","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/07/2013","start_date":" 03/07/2013","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"8dcde5f7-0991-4e36-9dba-a234fe02c2fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03187210","created_at":"2021-01-18T15:42:56.122Z","updated_at":"2024-07-02T16:35:04.707Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas","source_id_and_acronym":"NCT03187210","lead_sponsor":"Insel Gruppe AG, University Hospital Bern","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Adcetris (brentuximab vedotin) • melphalan"],"overall_status":"Suspended","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 11/02/2023","primary_completion_date":" 11/02/2023","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-09"},{"id":"0f098c9e-9aa5-495f-abd0-14af037e624a","acronym":"PACIFIC","url":"https://clinicaltrials.gov/study/NCT04745949","created_at":"2021-02-09T13:53:14.799Z","updated_at":"2024-07-02T16:35:05.970Z","phase":"Phase 2","brief_title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","source_id_and_acronym":"NCT04745949 - PACIFIC","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2025","study_completion_date":" 08/03/2025","last_update_posted":"2024-05-03"},{"id":"970ea094-a661-4898-85eb-a557dddaf167","acronym":"","url":"https://clinicaltrials.gov/study/NCT01979536","created_at":"2021-01-18T09:00:59.609Z","updated_at":"2024-07-02T16:35:06.864Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT01979536","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • dexamethasone • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2024-04-30"},{"id":"b856a9ee-5034-47d2-9d2b-077b726e6bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02744612","created_at":"2021-01-18T13:26:48.184Z","updated_at":"2024-07-02T16:35:07.083Z","phase":"Phase 2","brief_title":"Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT02744612","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/20/2016","start_date":" 06/20/2016","primary_txt":" Primary completion: 03/03/2021","primary_completion_date":" 03/03/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-29"},{"id":"786063a2-0831-4b28-b56e-5cb86d6097eb","acronym":"RG1713010","url":"https://clinicaltrials.gov/study/NCT01703949","created_at":"2021-01-18T07:24:57.178Z","updated_at":"2024-07-02T16:35:08.657Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma","source_id_and_acronym":"NCT01703949 - RG1713010","lead_sponsor":"University of Washington","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/20/2013","start_date":" 03/20/2013","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-19"},{"id":"6a4ac4b8-ac4e-46a2-bb00-4f42aa1f1efd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01920932","created_at":"2021-01-18T08:40:01.212Z","updated_at":"2024-07-02T16:35:11.441Z","phase":"Phase 2","brief_title":"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","source_id_and_acronym":"NCT01920932","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 08/12/2013","start_date":" 08/12/2013","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-04-04"}]